Cartalax is a synthetic tripeptide, Ala-Glu-Asp (AED), and one of the short peptide bioregulators associated with the Khavinson research group. It is sold on the research-chemical market for cartilage and connective-tissue applications and is not an approved drug in any jurisdiction.

Does Cartalax help cartilage or joints?

There is no published clinical evidence that it does. No controlled human trials of Cartalax exist, and no validated mechanism in cartilage or chondrocytes has been demonstrated in the peer-reviewed literature. The marketed cartilage and joint-repair use rests on theory rather than outcome data.

Is Cartalax approved?

No. Cartalax has no marketing authorisation from the FDA, the EMA, or any comparable regulator, and it is not approved as a drug anywhere. It is sold as a research chemical or peptide bioregulator, which is a commercial description rather than a regulatory category.

Human safety data are lacking. No adverse-effect profile has been characterised in people, and controlled safety data are absent. Because it is unapproved and sold for research use, its purity, long-term effects, and interactions are not established. This information is educational and not medical advice.

How is Cartalax different from Epitalon?

Both are short Khavinson-type peptide bioregulators, but they are different molecules: Cartalax is the tripeptide AED, while Epitalon is the tetrapeptide AEDG. They are marketed for different purposes, cartilage support versus longevity, and neither is an approved medicine or supported by controlled human trials.

Where can I buy Cartalax and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Recovery / Regeneration

Buy Cartalax – Vendors, Prices, Testing and Evidence

Buy Cartalax

Also known as: Ala-Glu-Asp · AED · AED peptide

Evidence grade C — Early / PreclinicalRisk flag

Short answer

A synthetic Khavinson-type tripeptide (Ala-Glu-Asp) marketed for cartilage and connective-tissue support. Published data are limited to in vitro and mechanistic work from a single research tradition; there are no clinical trials, and the marketed joint/cartilage use is essentially unsupported.

Where can you buy Cartalax?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

Cartalax is a synthetic short peptide with the sequence Ala-Glu-Asp (AED), one of the 'peptide bioregulators' associated with the research group led by Vladimir Khavinson. It is sold on the research-chemical market for cartilage and connective-tissue applications and is not an approved drug in any jurisdiction.

What is not established?

Safety

Human safety data are lacking. As an unapproved peptide sold for research use, its purity, long-term effects, and interactions are not established.

Regulatory status

Not approved as a drug in any jurisdiction (no FDA, EMA, or comparable marketing authorisation). Sold as a 'research chemical' / peptide bioregulator.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy Cartalax: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	Cartalax research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

Cartalax research product

Code PEPTIDES10 −10% · discount code details

What is it?

Research and evidence

Cartalax is a synthetic tripeptide with the sequence alanine-glutamic acid-aspartic acid, usually written Ala-Glu-Asp and abbreviated AED. It belongs to the family of short peptide bioregulators associated with the research group led by Vladimir Khavinson, and it is sold on the research-chemical market for cartilage and connective-tissue support. It is not an approved drug in any jurisdiction: no FDA, EMA, or comparable marketing authorisation exists for it. peptides.cx catalogues it under Recovery / Regeneration with an evidence grade of C, which here reflects a thin and one-sided literature rather than a body of mixed clinical results.

What exists in the peer-reviewed record is in vitro work, drawn largely from a single research tradition. Published studies report that the AED peptide can influence the differentiation of cultured human stem cells, and Khavinson-group papers hypothesise that short peptides of this kind interact with DNA and chromatin to modulate gene transcription. That remains a hypothesis rather than a demonstrated mechanism. No specific, validated action in cartilage or chondrocytes has been shown in the peer-reviewed literature, there are no controlled human trials of Cartalax, and independently replicated animal efficacy studies for cartilage are scarce to absent in the indexed literature. The gap between what Cartalax is marketed for and what has actually been measured is wide, and the joint-repair claim is best read as essentially unsupported.

Human safety data are lacking for the same reason efficacy data are lacking. As an unapproved peptide sold for research use, its purity, long-term effects, and interactions are not established, and no adverse-effect profile has been characterised in people. Cartalax is often discussed alongside related bioregulators such as AEDG, better known as Epitalon, in longevity and joint-health circles, and it shares their central problem: an appealing theory with very little outcome data behind it. This page is an educational reference summarising what the science does and does not show; it is not medical advice, and it does not provide dosing, protocols, or sourcing guidance.

Evidence grade: C

There are no controlled human trials of Cartalax. The peer-reviewed work on the AED peptide is in vitro and comes largely from one research group. No published clinical evidence supports the marketed cartilage or joint-repair claims. Direct, independently replicated animal efficacy studies of Cartalax for cartilage are scarce to absent in the indexed literature; most supporting material is mechanistic or review-level rather than controlled in vivo data.

Human evidence

Animal and preclinical evidence

Direct, independently replicated animal efficacy studies of Cartalax for cartilage are scarce to absent in the indexed literature; most supporting material is mechanistic or review-level rather than controlled in vivo data.

Proposed mechanisms

Proposed to act as a peptide bioregulator affecting gene expression; in vitro work reports the AED peptide can influence differentiation of cultured human stem cells
Khavinson-group publications hypothesise such short peptides interact with DNA/chromatin to modulate transcription, but this remains a hypothesis
A specific, validated mechanism in cartilage or chondrocytes has not been demonstrated in peer-reviewed literature

Safety concerns and known side effects

Human safety data are lacking. As an unapproved peptide sold for research use, its purity, long-term effects, and interactions are not established.

No adverse-effect profile has been characterised in humans; controlled safety data are absent

Regulatory status

Not approved as a drug in any jurisdiction (no FDA, EMA, or comparable marketing authorisation). Sold as a 'research chemical' / peptide bioregulator.

Frequently asked questions about Cartalax

What is Cartalax?: Cartalax is a synthetic tripeptide, Ala-Glu-Asp (AED), and one of the short peptide bioregulators associated with the Khavinson research group. It is sold on the research-chemical market for cartilage and connective-tissue applications and is not an approved drug in any jurisdiction.
Does Cartalax help cartilage or joints?: There is no published clinical evidence that it does. No controlled human trials of Cartalax exist, and no validated mechanism in cartilage or chondrocytes has been demonstrated in the peer-reviewed literature. The marketed cartilage and joint-repair use rests on theory rather than outcome data.
What research exists on Cartalax?: The peer-reviewed work on the AED peptide is in vitro and comes largely from one research group, including reports that it can influence the differentiation of cultured human stem cells. Direct, independently replicated animal efficacy studies for cartilage are scarce to absent, and human trials do not exist.
Is Cartalax approved?: No. Cartalax has no marketing authorisation from the FDA, the EMA, or any comparable regulator, and it is not approved as a drug anywhere. It is sold as a research chemical or peptide bioregulator, which is a commercial description rather than a regulatory category.
Is Cartalax safe?: Human safety data are lacking. No adverse-effect profile has been characterised in people, and controlled safety data are absent. Because it is unapproved and sold for research use, its purity, long-term effects, and interactions are not established. This information is educational and not medical advice.
How is Cartalax different from Epitalon?: Both are short Khavinson-type peptide bioregulators, but they are different molecules: Cartalax is the tripeptide AED, while Epitalon is the tetrapeptide AEDG. They are marketed for different purposes, cartilage support versus longevity, and neither is an approved medicine or supported by controlled human trials.
Where can I buy Cartalax and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

Grouped with other Khavinson 'bioregulator' peptides in longevity and joint-health discussionsMarketed for cartilage and connective-tissue support largely on the basis of theory rather than outcome dataOften mentioned alongside related peptides such as AEDG (Epitalon)

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: July 18, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10